- Home
- MODD vs ONCY Comparison
MODD vs ONCY Comparison
Compare MODD & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ONCY
- Stock Information
- Founded
- MODD 1998
- ONCY 1998
- Country
- MODD United States
- ONCY Canada
- Employees
- MODD N/A
- ONCY N/A
- Industry
- MODD Industrial Specialties
- ONCY Pharmaceuticals and Biotechnology
- Sector
- MODD Health Care
- ONCY Health Care
- Exchange
- MODD Nasdaq
- ONCY Nasdaq
- Market Cap
- MODD 46.3M
- ONCY 49.1M
- IPO Year
- MODD N/A
- ONCY 1999
- Fundamental
- Price
- MODD $0.86
- ONCY $0.34
- Analyst Decision
- MODD
- ONCY Strong Buy
- Analyst Count
- MODD 0
- ONCY 4
- Target Price
- MODD N/A
- ONCY $4.33
- AVG Volume (30 Days)
- MODD 78.5K
- ONCY 820.6K
- Earning Date
- MODD 06-20-2025
- ONCY 05-14-2025
- Dividend Yield
- MODD N/A
- ONCY N/A
- EPS Growth
- MODD N/A
- ONCY N/A
- EPS
- MODD N/A
- ONCY N/A
- Revenue
- MODD N/A
- ONCY N/A
- Revenue This Year
- MODD N/A
- ONCY N/A
- Revenue Next Year
- MODD N/A
- ONCY N/A
- P/E Ratio
- MODD N/A
- ONCY N/A
- Revenue Growth
- MODD N/A
- ONCY N/A
- 52 Week Low
- MODD $0.68
- ONCY $0.34
- 52 Week High
- MODD $2.65
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- MODD 39.61
- ONCY 23.40
- Support Level
- MODD $0.75
- ONCY $0.37
- Resistance Level
- MODD $0.90
- ONCY $0.45
- Average True Range (ATR)
- MODD 0.07
- ONCY 0.04
- MACD
- MODD -0.01
- ONCY -0.01
- Stochastic Oscillator
- MODD 39.29
- ONCY 0.50
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.